Skip to content
ClinCalc Pro
Menu
Stimulant Laxative — Constipation in Children

Senna (Paediatric)

Brand names: Senokot, Ex-Lax

Senna is a stimulant laxative used in children, commonly as a second agent alongside an osmotic laxative in the management of constipation and faecal impaction.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its anthraquinone glycosides are activated by colonic bacteria to stimulate the myenteric plexus, increasing intestinal motility and reducing water absorption to promote a bowel movement.

Prescribing in practice

  • It should not be used where intestinal obstruction is suspected, and is generally combined with an osmotic/softening laxative in children rather than used alone for impaction.
  • Onset is delayed by several hours, so timing should account for this and avoid disrupting school or sleep.
  • Liquid and tablet formulations differ in strength; check the correct preparation and dose against a children's formulary.

Monitoring

Monitor stool frequency and consistency and adjust the dose to maintain soft, regular stools, reviewing the ongoing need as a maintenance regimen is established.

Counselling the patient

  • It usually takes several hours to work, so plan the timing accordingly.
  • Continue regular maintenance treatment even once stools improve, as advised.
  • Encourage adequate fluids and fibre alongside the medicine.

Evidence & guidelines

Stimulant laxatives such as senna feature in NICE guidance on childhood constipation as add-on therapy when an osmotic laxative alone is insufficient.

Reference: NICE NG90 (Constipation in Children); ESPGHAN Childhood Constipation Guidelines 2014; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.